[镓]Ga-FAPI-04 PET/CT成像在肝血管相关间充质瘤中的表现：与[氟]FDG PET/CT的比较
Performance of [Ga]Ga-FAPI-04 PET/CT imaging in hepatic vascular-associated mesenchymal tumor: comparison with [F]FDG PET/CT.
作者信息
Cheng Zixia, Zhou Jianyuan, Kuang Dong, Zuo Rui, Zhu Dongling, Pang Hua
机构信息
Department of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
出版信息
Eur J Nucl Med Mol Imaging. 2025 Jul 24. doi: 10.1007/s00259-025-07446-1.
PURPOSE
To assess the efficacy of [Ga]Ga-FAPI-04 PET/CT in detecting hepatic vascular-associated mesenchymal tumor (HVAMT), including hepatic hemangioma (HH), hepatic epithelioid hemangioendothelioma (HEHE), and hepatic perivascular epithelioid cell tumor (PEComa), and to compare its efficacy with that of [F]FDG PET/CT.
METHODS
A retrospective analysis was conducted on 31 cases of HVAMTs from a prospective parent study (ChiCTR2000039099), including 25 cases of HH (35 lesions), 2 cases of HEHE (18 lesions), and 4 cases of PEComa (6 lesions). All patients underwent both [¹⁸F]FDG and [⁶⁸Ga]Ga-FAPI-04 PET/CT within one week of each other. The detection rates of both imaging modalities in detecting HVAMTs were compared. SUVmax, tumor-to-background ratio (TBR), and correlation between the longest diameter (LD) of lesions and SUVmax were analyzed. The imaging results were validated with pathological evaluations and follow-up examinations.
RESULTS
The detection rate for each tumor type by [F]FDG and [Ga]Ga-FAPI-04 PET/CT was as follows: HH (2.9% [1/35] vs. 54.3% [19/35], p < 0.001); HEHE (27.8% [5/18] vs. 88.9% [16/18], p = 0.001); PEComa (83.3% [5/6] vs. 100% [6/6]); HVAMT (18.6% [11/59] vs. 69.5% [41/59], p < 0.001). Although [Ga]Ga-FAPI-04 PET/CT yielded lower median SUVmax than [F]FDG PET/CT in HH (1.30 vs. 2.30, p < 0.001) and HVAMT (1.60 vs. 2.70, p = 0.001), it exhibited higher TBR than the latter for HH (1.83 vs. 1.07, p < 0.001), HEHE (2.13 vs. 1.19, p < 0.001), PEComa (8.85 vs. 2.28, p = 0.088), and HVAMT (2.25 vs. 1.14, p < 0.001), respectively. In addition, the SUVmax of [Ga]Ga-FAPI-04 PET/CT showed a significant positive correlation with the LD of lesion in HH (r = 0.777, p < 0.001), HEHE (r = 0.836, p < 0.001), PEComa (r = 0.829, p = 0.042), and HVAMT (r = 0.676, p < 0.001). No such correlation was observed in [F]FDG PET/CT.
CONCLUSION
[Ga]Ga-FAPI-04 PET/CT was more sensitive than [F]FDG PET/CT in HVAMTs detection. However, the possibility of lesions being HVMATs should also be evaluated when detecting other common liver tumors using [Ga]Ga-FAPI-04 PET/CT.
TRIAL REGISTRATION
Chinese Clinical Trial Registry ChiCTR2000039099. Registered 17 October 2020.
目的
评估[⁶⁸Ga]Ga-FAPI-04 PET/CT在检测肝血管相关间叶性肿瘤（HVAMT）中的效能，包括肝血管瘤（HH）、肝上皮样血管内皮瘤（HEHE）和肝血管周上皮样细胞肿瘤（PEComa），并将其效能与[¹⁸F]FDG PET/CT进行比较。
方法
对一项前瞻性母研究（ChiCTR2000039099）中的31例HVAMT患者进行回顾性分析，其中包括25例HH（35个病灶）、2例HEHE（18个病灶）和4例PEComa（6个病灶）。所有患者在一周内先后接受了[¹⁸F]FDG和[⁶⁸Ga]Ga-FAPI-04 PET/CT检查。比较两种成像方式检测HVAMT的检出率。分析SUVmax、肿瘤与背景比值（TBR）以及病灶最长径（LD）与SUVmax之间的相关性。成像结果通过病理评估和随访检查进行验证。
结果
[¹⁸F]FDG和[⁶⁸Ga]Ga-FAPI-04 PET/CT对各肿瘤类型的检出率如下：HH（2.9%[1/35]对54.3%[19/З5]，p<0.001）；HEHE（27.8%[5/18]对88.9%[16/18]，p = 0.001）；PEComa（83.3%[5/6]对100%[6/6]）；HVAMT（18.6%[11/59]对69.5%[4I/59]，p<0.001）。虽然在HH（1.30对2.30，p<0.001）和HVAMT（1.60对2.70，p = 0.001）中，[⁶⁸Ga]Ga-FAPI-04 PET/CT的SUVmax中位数低于[¹⁸F]FDG PET/CT，但在HH（1.83对1.07，p<0.001）、HEHE（2.13对1.19，p<0.001）、PEComa（8.85对2.28，p = 0.088）和HVAMT（2.25对1.14，p<0.001）中，[⁶⁸Ga]Ga-FAPI-04 PET/CT的TBR高于[¹⁸F]FDG PET/CT。此外，[⁶⁸Ga]Ga-FAPI-04 PET/CT的SUVmax在HH（r = 0.777，p<0.001）、HEHE（r = 0.836，p<0.001）、PEComa（r = 0.829，p = 0.042）和HVAMT（r = 0.676，p<0.001）中与病灶LD呈显著正相关。在[¹⁸F]FDG PET/CT中未观察到这种相关性。
结论
[⁶⁸Ga]Ga-FAPI-04 PET/CT在检测HVAMT方面比[¹⁸F]FDG PET/CT更敏感。然而，在使用[⁶⁸Ga]Ga-FAPI-04 PET/CT检测其他常见肝脏肿瘤时，也应评估病灶为HVMAT的可能性。
试验注册
中国临床试验注册中心ChiCTR2000039099。2020年10月17日注册。
Zotero 插件